# Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference
Canonical URL: https://biopharmsignal.com/news/CLNN/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor--111e7723
Ticker: CLNN
Company: Clene Inc.
Source: Clene Inc.
Published: 2025-11-20 13:00 EST
## Summary

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene...

## Article Body
Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate at the Benchmark 14 th Annual Discovery One-on-One Investor Conference by hosting 1x1 investor meetings.

Conference Details Date: December 4, 2025 Location: New York, New York Format: 1x1 meetings (contact your Benchmark Representative)

About Clene Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8 ® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8 ® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn .

Investor Contact Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com 617-283-2856
## Recent Company News
- 2026-05-14 12:00 EST — [Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights](https://biopharmsignal.com/news/CLNN/clene-reports-first-quarter-2026-financial-results-and-recent-operating-highligh-05f09938) — Source: Clene Inc.
- 2026-05-05 12:45 EST — [Clene Announces $7 Million Underwritten Offering of Common Stock](https://biopharmsignal.com/news/CLNN/clene-announces-7-million-underwritten-offering-of-common-stock-ea05bb73) — Source: Clene Inc.
- 2026-05-05 12:00 EST — [Clene to Present at Upcoming May Conferences](https://biopharmsignal.com/news/CLNN/clene-to-present-at-upcoming-may-conferences-e4de6669) — Source: Clene Inc.
- 2026-05-04 12:00 EST — [After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS](https://biopharmsignal.com/news/CLNN/after-successful-fda-meeting-clene-filing-accelerated-approval-nda-for-als-ad6256ad) — Source: Clene Inc.
- 2026-03-12 12:00 EST — [Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights](https://biopharmsignal.com/news/CLNN/clene-reports-full-year-2025-financial-results-and-recent-operating-highlights-b436e9a7) — Source: Clene Inc.
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)